ALLO Allogene Therapeutics Inc

Price (delayed)

$31.60

Market cap

$4.43B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.14

Enterprise value

$4.27B

Sector: Healthcare
Industry: Biotechnology

Highlights

Allogene Therapeutics's equity has surged by 81% YoY but it has decreased by 3.8% QoQ
ALLO's quick ratio is down by 23% since the previous quarter but it is up by 12% year-on-year
The EPS has plunged by 127% YoY
The net income has shrunk by 58% YoY and by 7% QoQ

Key stats

What are the main financial stats of ALLO
Market
Shares outstanding
140.28M
Market cap
$4.43B
Enterprise value
$4.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$242.84M
EBITDA
-$235.54M
Free cash flow
-$218.05M
Per share
EPS
-$2.14
Free cash flow per share
-$1.72
Book value per share
$8.03
Revenue per share
$0
TBVPS
$9.62
Balance sheet
Total assets
$1.22B
Total liabilities
$103.77M
Debt
$0
Equity
$1.12B
Working capital
$803.93M
Liquidity
Debt to equity
0
Current ratio
17.04
Quick ratio
16.97
Net debt/EBITDA
0.71
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-25%
Return on equity
-27.6%
Return on invested capital
-32.8%
Return on capital employed
-20.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
-2.44%
1 week
12.1%
1 month
16.43%
1 year
24.8%
YTD
25.2%
QTD
25.2%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$253.46M
Net income
-$242.68M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 58% YoY and by 7% QoQ
ALLO's operating income is down by 49% year-on-year and by 5% since the previous quarter

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
3.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 127% YoY
Allogene Therapeutics's equity has surged by 81% YoY but it has decreased by 3.8% QoQ
ALLO's price to book (P/B) is 15% less than its last 4 quarters average of 4.6

Efficiency

How efficient is Allogene Therapeutics business performance
ALLO's return on invested capital is down by 25% year-on-year but it is up by 11% since the previous quarter
The return on assets has declined by 20% year-on-year but it has increased by 7% since the previous quarter
The return on equity has declined by 19% year-on-year but it has increased by 8% since the previous quarter

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
The company's total assets has surged by 76% YoY but it fell by 2.9% QoQ
The total liabilities has increased by 37% year-on-year and by 9% since the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
Allogene Therapeutics's equity has surged by 81% YoY but it has decreased by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.